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In Southeast Asia, ␤-thalassemia, and hemoglobin (Hb) E are common. The frequencies of the traits can be as high as 3-9% for ␤ 0 thalassemia, and up to 54% or higher for Hb E. 1 Patients with ␤-thalassemia/Hb E can be as severely affected as those with homozygous ␤-thalassemia or Cooley's anemia. At present, allogeneic hematopoietic stem cell transplantation is the only curative therapy for thalassemia. Issaragrisil et al 2 were the first to report successful use of matched related cord blood transplantation (CBT) in a child with ␤-thalassemia/Hb E disease. In the published literature review, all thalassemic patients treated with CBT received fully matched cord blood (CB). [3] [4] [5] [6] We report our experience of utilizing mismatched CBT in a child with severe ␤-thalassemia/Hb E disease.
A 3-year-old female was diagnosed with ␤ 0 -thalassemia/Hb E at 4 months of age when she presented with anemia. Her steady-state hemoglobin level was 7 gm/dl. The result of hemoglobin typing was: Hb F 58.2%, Hb E 41.8%. The patient required packed red blood cell transfusion on three occasions. Her father had ␤-thalassemia trait and her mother had Hb E trait. Analysis of ␤ globin gene mutation demonstrated a nonsense mutation at codon 17. The patient's HLA typing was: A 2,10; B 62,46; Cw 1,6; Bw 6, −; DR B1* 1502,1401; DR 51,52; DQ A1* 0101,0104; DQ B1* 0501,0502.
During a subsequent maternal pregnancy, cord blood was collected at the time of delivery. The male fetus was homozygous for wild-type ␤-thalassemia gene. The volume of collected cord blood was 150 ml. The total numbers of nucleated cells and CD34 + cells were 6.1 × 10 7 cells/kg and 1.58 × 10 5 cells/kg, respectively. Cord blood typing was: A 10,11; B 62,48; Cw 6,8; Bw 6, -; DR B1* 1502,1401; DR 51,52; DQ A1* 0101,0104; DQ B1* 0501,0503 (HLA class I by serology, and class II by high resolution sequencespecific primer DNA typing). The patient shared one haplotype with his brother. However, no mismatch in HLA-DR B1* and HLA-DQ A1* was noted. Due to inability to access international bone marrow donor registries from Thailand, we decided to perform CBT instead of a matched unrelated BMT in this patient. The preparative regimen consisted of busulfan (BU) 5 mg/kg/day (day −11 to day −8), cyclophosphamide 50 mg/kg/day (day −7 to day −4), and antithymocyte globulin (ATG) 20 mg/kg/day (day −3 to day −2). The viability of CB at the time of infusion was 86%. GVHD prophylaxis comprised methylprednisolone (1 mg/kg/day) starting on day −1 for 30 days and cyclosporin A starting on day −1 at a dose of 3 mg/kg i.v. every 12 h until day +30 when it was given orally for 6 months.
Neutrophil engraftment (ANC Ͼ0.5 × 10 9 /l) occurred on day +25, and platelet engraftment (Ͼ20.0 × 10 9 /l) on day +60. She became red blood cell transfusion independent on day +72. Her course of CBT was complicated by acute GVHD grade II. However, it resolved with ATG and methylprednisolone administration. A chimerism study performed on day +240 showed full donor chimerism. This was detected by a FISH technique using probes for the X and Y chromosomes which showed Y (donor) cells 99.4% and XX cells (recipient) 0.6%. There was also a switch in blood group from AB+ pre transplant to B+ post transplant. Serial hemoglobin levels and hemoglobin typing are summarized in Table 1 . Unfortunately on day +300 the patient died of Salmonella sepsis. She had also developed limited chronic GVHD and she was receiving steroids at the time of death from sepsis.
We believe that performing this CBT early in the disease course and thus avoiding frequent blood transfusion, adding ATG, and using GVHD prophylaxis without methotrexate allowed a successful engraftment in this case. An identical HLA-DR locus between donor and recipient may have contributed to excellent engraftment with minimal rejection. GVHD and using a cord blood graft in this patient may have contributed to delayed immune reconstitution. This Table 1 Serial hemoglobin levels and hemoglobin typing pre and post cord blood transplantation (CBT) 
